Jazz Pharmaceuticals plc Defined Contribution Plan, Cost
Jazz Pharmaceuticals plc (JAZZ) reported Defined Contribution Plan, Cost of $8.20 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2020-02-25
- Jazz Pharmaceuticals plc defined contribution plan, cost for fiscal 2019 was $8.20M, a 28.13% increase from fiscal 2018.
- Jazz Pharmaceuticals plc defined contribution plan, cost for fiscal 2018 was $6.40M, a 16.36% increase from fiscal 2017.
- Jazz Pharmaceuticals plc defined contribution plan, cost for fiscal 2017 was $5.50M, a 61.76% increase from fiscal 2016.
- Jazz Pharmaceuticals plc defined contribution plan, cost for fiscal 2016 was $3.40M, a 54.55% increase from fiscal 2015.
| Period end | Defined Contribution Plan, Cost 12 month |
|---|---|
| 2019-12-31 | $8.20M 10-K · filed 2020-02-25 |
| 2018-12-31 | $6.40M 10-K · filed 2020-02-25 |
| 2017-12-31 | $5.50M 10-K · filed 2020-02-25 |
| 2016-12-31 | $3.40M 10-K · filed 2019-02-26 |
| 2015-12-31 | $2.20M 10-K · filed 2018-02-27 |
| 2014-12-31 | $2.00M 10-K · filed 2017-02-28 |
| 2013-12-31 | $1.10M 10-K · filed 2016-02-23 |
| 2012-12-31 | $300.00K 10-K · filed 2015-02-24 |
| 2011-12-31 | $0.00 10-K · filed 2014-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |